3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Urinary Bladder Neoplasms
10
Pancreatic Neoplasms
7
Carcinoma, Merkel Cell
6
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Renal Cell
4
Recurrence
3
Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Stomach Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Carcinoma, Squamous Cell
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Cancer Resectable
1
Non-Muscle Invasive Bladder Neoplasms
1
Nasopharyngeal Neoplasms
1
Multiple Myeloma
1
Microsatellite Instability
1
Interventions
Fluorouracil
25
Oxaliplatin
24
Irinotecan
24
Leucovorin
23
Bevacizumab
23
Capecitabine
18
Cetuximab
15
Radiotherapy
6
Gene Expression Profiling
5
regorafenib
4
Immunohistochemistry
4
Gemcitabine
4
Folfox protocol
4
Colonoscopy
4
Cisplatin
4
Celecoxib
4
Amplified Fragment Length Polymorphism Analysis
4
Reverse Transcriptase Polymerase Chain Reaction
3
Receptor Protein-Tyrosine Kinases
3
Polymerase Chain Reaction
3
Nivolumab
3
Mitomycin
3
Doxorubicin
3
Cyclophosphamide
3
Cholecalciferol
3
Biopsy
3
Aspirin
3
sargramostim
2
pembrolizumab
2
ixabepilone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Colonic Neoplasms
×
avelumab
×
Clear all
NCT03827044
2022-10-07
POLEM
Royal Marsden NHS Foundation Trust
Phase 3
Terminated
30 enrolled